Immune-Based Drug Shows Potential Against Another Form of Lung Cancer
Patients with squamous cell non-small cell lung cancer who got nivolumab lived longer, had fewer side effectsContinue Reading
Patients with squamous cell non-small cell lung cancer who got nivolumab lived longer, had fewer side effectsContinue Reading
Damage to thinking and memory less than with radiation for entire brain, while survival is similar, study findsContinue Reading
Damage to thinking and memory less than with radiation for entire brain, while survival is similar, study findsContinue Reading
Compared to Yervoy, nivolumab more than doubled time to disease progression, researchers foundContinue Reading
DNA-modified virus serves as decoy to help target and destroy glioblastoma cells, researchers sayContinue Reading
Fewer die of ‘late effects’ from radiation, chemotherapy, study findsContinue Reading
No survival difference seen for patients spared surgery, study saysContinue Reading
Ibrutinib, obinutuzumab slowed progression of common leukemia, non-Hodgkin lymphomaContinue Reading
Study finds effect seems to extend to people exposed to secondhand smoke, tooContinue Reading
Patients given nivolumab reported fewer side effects, longer survival than those receiving usual chemo agentContinue Reading
© 2021 WeeklyMD.com - All Rights Reserved.